Clinical trials: Atherosclerotic Cardiovascular Disease (ASCVD)
Hyperlipidemia, Atherosclerotic Cardiovascular Disease (ASCVD)
PCSK9 Inhibitors in Hyperlipidemia and Atherosclerosis
PCSK9 inhibitors, including evolocumab and alirocumab, are lipid-lowering therapies used in patients with hyperlipidemia and atherosclerotic cardiovascular disease.
- Trial name
- NCT07856264
- Volunteers
- 100 people
- Sponsor
- Fundación Santa Fe de Bogota
Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
This fictional study is an example of a ClinicalTrials.gov-style record. It describes a Phase 1/2 trial evaluating the safety and tolerability of TB-500 (a 17-23 fragment of thymosin beta 4) versus placebo in adults with stable…
- Trial name
- TBRIDGE-CV (NCT07487363)
- Testing
- TB-500
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Hudson Biotech
Diabetes Mellitus, Type 2, Dyslipidemias
Curcumin's Effect on Diabetic Patients With Atherosclerotic Cardiovascular Risk
The aim of the study is to assess the safety and efficacy of Curcumin supplementation in combination to the conventional therapy in improving the clinical outcomes, oxidative stress and inflammation in diabetic patients with risk…
- Conditions
- Diabetes Mellitus, Type 2, Dyslipidemias, Hypertension
- Trial name
- NCT05753436
- Testing
- Puritans Pride Turmeric curcumin® 500 mg
- Where
- Egypt
- Volunteers
- 72 people
- Sponsor
- Ain Shams University
Atherosclerotic Cardiovascular Disease (ASCVD)
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD who have elevated lipoprotein(a) (Lp(a)), and who are on…
- Trial name
- ADD-VANTAGE (NCT06813911)
- Testing
- Pelacarsen, Inclisiran
- Where
- 94 sites in United States, China and 9 more
- Volunteers
- 246 people
- Sponsor
- Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Diseases (ASCVD)
Prospective Assessment of Atherosclerotic Cardiovascular Disease (ASCVD) Risk
This study aims to conduct a 10-year follow-up to assess ASCVD risk in Pakistan among individuals aged 30 years and above without a known history of ASCVD.
- Trial name
- NCT06316453
- Testing
- Evaluating ASCVD risk over 10 and 30 year and lifetime
- Where
- Pakistan
- Volunteers
- 3,513 people, healthy volunteers welcome
- Sponsor
- Advanced Education & Research Center
Lipoprotein Disorder
Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)
This is a phase 2, double-blind, randomized, placebo-controlled, multi-center, dose-finding study to evaluate the efficacy and safety of Kylo-11 administered subcutaneously compared to placebo in participants with ASCVD and…
- Trial name
- NCT07327840
- Where
- 48 sites in United States, China
- Volunteers
- 204 people
- Sponsor
- Kylonova (Xiamen) Biopharma co., LTD.